会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Sampling apparatus, and testing apparatus
    • 取样装置和检测装置
    • US20060279274A1
    • 2006-12-14
    • US11387445
    • 2006-03-23
    • Tsutomu Yamanaka
    • Tsutomu Yamanaka
    • G01R31/28
    • G01R31/31922G01R31/31928
    • Each channel comprises: an AD converter which converts a signal value of a corresponding input signal into a digital value in response to a received sampling clock; a counter which counts the pulses of the sampling clock; memory which sequentially stores the digital values at addresses corresponding to the counted values of the counter; a transmission/reception unit which outputs the counted value of the counter at a point in time at which acquisition of the waveform of the input signal is to be started in a case that the channel is set to be a main channel beforehand, and which receives the start data counted value from the main channel in a case that the channel is set to be a sub-channel; and an output unit which sequentially outputs the digital values stored in the memory with the digital value stored at the address corresponding to the start data counted value as the start data.
    • 每个通道包括:AD转换器,其响应于接收到的采样时钟将相应输入信号的信号值转换成数字值; 计数采样时钟脉冲的计数器; 存储器,其顺序地将数字值存储在与计数器的计数值对应的地址处; 在通道被预先设定为主通道的情况下,在输入信号的波形的获取的时间点输出计数器的计数值的发送/接收单元,并且接收 在将信道设置为子信道的情况下,来自主信道的起始数据计数值; 以及输出单元,其以存储在与开始数据计数值相对应的地址的数字值作为开始数据顺序输出存储在存储器中的数字值。
    • 2. 发明授权
    • Benzopyran compound and its pharmaceutical use
    • 苯并吡喃化合物及其药物用途
    • US5318969A
    • 1994-06-07
    • US897253
    • 1992-06-11
    • Tsutomu YamanakaToshio SekiTohru NakajimaOsamu Yaoka
    • Tsutomu YamanakaToshio SekiTohru NakajimaOsamu Yaoka
    • C07D311/68A61K31/35A61K31/352A61K31/443A61K31/4433A61K31/455A61K31/50A61K31/535A61P9/08A61P9/10A61P9/12A61P25/02C07D311/70C07D311/96C07D405/04C07D405/12C07D407/12C07D409/12
    • C07D405/12C07D311/68C07D407/12
    • A benzopyran compound of the general formula (I) ##STR1## wherein A represents --OR.sup.1 or --NH--COR.sup.2 ; R.sup.3 represents hydrogen, a lower alkyl, a lower alkoxy, amino, a mono- or di-lower alkylamino, an amino-lower alkyl, a hydroxy-lower alkyl, a halo-lower alkyl, a lower alkoxy-lower alkyl, an acyloxy-lower alkyl, a lower alkoxycarbonyl-lower alkyl, an aryl or a heteroaryl, or R.sup.2 and R.sup.3 combinedly together form an alkylene having 1 to 2 carbon atoms; R.sup.4 and R.sup.5 are the same or different, and respectively represent hydrogen or a lower alkyl, or combinedly together form an alkylene having 2 to 5 carbon atoms; R.sup.6 represents hydroxyl group, formyloxy, an alkanoyloxy, a haloalkanoyloxy, a lower alkoxycarbonyloxy, an aroyloxy, a heteroaroyloxy, carbamoyloxy, a mono- or di-lower alkylcarbamoyloxy and R.sup.7 represents hydrogen, or R.sup.6 and R.sup.7 combinedly together form a bond and X and Y are the same or different, and respectively represent hydrogen, halogen, nitro, cyano, a lower alkyl, a lower alkoxy, a halo-lower alkyl, carboxyl, formyl, an alkanoyl, an aroyl, a halo-alkanoyl, carbamoyl, a lower alkylsulfinyl, an arylsulfinyl, a lower alkylsulfonyl, an arylsulfonyl, sulfonamido or a mono- or di-lower alkylsulfonamido, or their pharmaceutically acceptable salts and its pharmaceutical use.
    • 通式(I)的苯并吡喃化合物其中A表示-OR1或-NH-COR2; R 3表示氢,低级烷基,低级烷氧基,氨基,一或二低级烷基氨基,氨基 - 低级烷基,羟基 - 低级烷基,卤代低级烷基,低级烷氧基 - 低级烷基,酰氧基 低级烷基,低级烷氧基羰基 - 低级烷基,芳基或杂芳基,或R2和R3组合在一起形成具有1至2个碳原子的亚烷基; R4和R5相同或不同,分别表示氢或低级烷基,或者组合在一起形成具有2-5个碳原子的亚烷基; R6表示羟基,甲酰氧基,烷酰氧基,卤代烷酰氧基,低级烷氧基羰氧基,芳酰氧基,杂芳氧基,氨基甲酰氧基,一或二低级烷基氨基甲酰氧基,R7表示氢,或R6和R7组合在一起形成键,X和 Y分别相同或不同,分别表示氢,卤素,硝基,氰基,低级烷基,低级烷氧基,卤代低级烷基,羧基,甲酰基,烷酰基,芳酰基,卤代烷酰基,氨基甲酰基, 低级烷基亚磺酰基,芳基亚磺酰基,低级烷基磺酰基,芳基磺酰基,亚磺酰氨基或单 - 或二 - 低级烷基亚磺酰氨基,或其药学上可接受的盐及其药物用途。
    • 6. 发明授权
    • Benzopyran compound and its pharmaceutical use
    • US5143936A
    • 1992-09-01
    • US672657
    • 1991-03-21
    • Tsutomu YamanakaToshio SekiTohru NakajimaOsamu Yaoka
    • Tsutomu YamanakaToshio SekiTohru NakajimaOsamu Yaoka
    • C07D311/68A61K31/35A61K31/352A61K31/443A61K31/4433A61K31/455A61K31/50A61K31/535A61P9/08A61P9/10A61P9/12A61P25/02C07D311/70C07D311/96C07D405/04C07D405/12C07D407/12C07D409/12
    • C07D405/12C07D311/68C07D407/12
    • A benzopyran compound of the general formula (I) ##STR1## wherein A represents --OR.sup.1 or --NH--COR.sup.2 (wherein R.sup.1 represents hydrogen, a lower alkyl, formyl, an alkanoyl, an aroyl or an aralkyl and R.sup.2 represents hydrogen, a lower alkyl, a lower alkoxy, amino, mono- or di-lower alkylamino, an amino-lower alkyl, a hydroxy-lower alkyl, a halo-lower alkyl, a lower alkoxy-lower alkyl, an acyloxy-lower alkyl, a lower alkoxycarbonyl-lower alkyl, an aryl or a heteroaryl); R.sup.3 represents hydrogen, a lower alkyl, a lower alkoxy, amino, a mono- or di-lower alkylamino, an amino-lower alkyl, a hydroxy-lower alkyl, a halo-lower alkyl, a lower alkoxy-lower alkyl, an acyloxy-lower alkyl, a lower alkoxycarbonyl-lower alkyl, an aryl or a heteroaryl, or R.sup.2 and R.sup.3 combinedly together form an alkylene having 1 to 2 carbon atoms; R.sup.4 and R.sup.5 are the same or different, and respectively represent hydrogen or a lower alkyl, or combinedly together form an alkylene having 2 to 5 carbon atoms; R.sup.6 represents hydroxyl group, formyloxy, an alkanoyloxy, a haloalkanoyloxy, a lower alkoxycarbonyloxy, an aroyloxy, a heteroaroyloxy, carbamoyloxy, a mono- or di-lower alkycarbamoyloxy and R.sup.7 represents hydrogen, or R.sup.6 and R.sup.7 combinedly together form a bond and X and Y are the same or different, and respectively represent hydrogen, halogen, nitro, cyano, a lower alkyl, a lower alkoxy, a halo-lower alkyl, carboxyl, formyl, an alkanoyl, an aroyl, a halo-alkanoyl, carbamoyl, a lower alkylsulfinyl, an arylsulfinyl, a lower alkylsulfonyl, an arylsulfonyl, sulfonamido or a mono- or di-lower alkylsulfonamido, or their pharmaceutically acceptable salts and its pharmaceutical use.The compounds of the present invention exhibit remarkable and long lasting antihypertensive actions and peripheral vascular relaxant actions and therefore are useful as therapeutic medicines for hypertensive. Since they also display selective coronary vasodilating actions and the duration of actions are very long, they are of use as therapeutic medicines for cardiovascular disturbances such as angina pectoris and cardiac insufficiency.
    • 7. 发明授权
    • Ortho-aminomethylphenol compounds
    • 邻氨基甲基苯酚化合物
    • US4709095A
    • 1987-11-24
    • US853809
    • 1986-03-25
    • Tsutomu YamanakaOsamu Yaoka
    • Tsutomu YamanakaOsamu Yaoka
    • A61K31/15A61K31/35A61K31/352A61K31/47A61P7/10A61P9/12A61P25/04A61P29/00C07C67/00C07C239/00C07C251/48C07D215/42C07D311/68C07C131/00
    • C07D311/68
    • Ortho-aminomethylphenol compounds of the formula: ##STR1## wherein X is hydrogen or halogen, R is hydrogen or alkyl having 1 to 4 carbon atoms and A is alkyl having 1 to 4 carbon atoms, phenyl, benzyl or a bivalent radical selected from --(CH.sub.2).sub.3 -- and --O(CH.sub.2).sub.2 -- and joined together with the 3 or 5 position of the benzene nucleus to form a bicycle, or pharmaceutically acceptable salts thereof, a method of preparing said compounds and a pharmaceutical composition containing said compounds, are disclosed.Such compounds exhibit antiinflammatory, analgesic, diuretic and antihypertensive activities, so they are useful in the treatment for diseases caused by inflammation, edema or hypertension.
    • PCT No.PCT / JP85 / 00440 Sec。 371日期:1986年3月25日 102(e)日期1986年3月25日PCT提交1985年8月2日PCT公布。 出版物WO86 / 01201 日本:1986年2月27日。下式的邻氨基甲基苯酚化合物:其中X是氢或卤素,R是氢或具有1至4个碳原子的烷基,A是具有1至4个碳原子的烷基,苯基,苄基 或选自 - (CH 2)3 - 和-O(CH 2)2 - 的二价基团并且与苯核的3或5位相连接以形成自行车或其药学上可接受的盐,制备所述化合物的方法 和含有所述化合物的药物组合物。 这些化合物表现出抗炎,止痛,利尿和抗高血压活性,因此它们可用于治疗由炎症,水肿或高血压引起的疾病。
    • 10. 发明授权
    • Benzopyran compound and its pharmaceutical use
    • 苯并吡喃化合物及其药物用途
    • US5021432A
    • 1991-06-04
    • US340271
    • 1989-04-19
    • Tsutomu YamanakaToshio SekiTohru NakajimaOsamu Yaoka
    • Tsutomu YamanakaToshio SekiTohru NakajimaOsamu Yaoka
    • C07D311/68A61K31/35A61K31/352A61K31/443A61K31/4433A61K31/455A61K31/50A61K31/535A61P9/08A61P9/10A61P9/12A61P25/02C07D311/70C07D311/96C07D405/04C07D405/12C07D407/12C07D409/12
    • C07D405/12C07D311/68C07D407/12
    • A benzopyran compound of the general formula (I) ##STR1## wherein A represents --OR.sup.1 or --NH--COR.sup.2 (wherein R.sup.1 represents hydrogen, a lower alkyl, formyl, an alkanoyl, an aroyl or an aralkyl and R.sup.2 represents hydrogen, a lower alkyl, a lower alkoxy, amino, mono- or di-lower alkylamino, an amino-lower alkyl, a hydroxy-lower alkyl, a halo-lower alkyl, a lower alkoxy-lower alkyl, an acyloxy-lower alkyl, a lower alkoxy-carbonyl-lower alkyl, an aryl or a heteroaryl); R.sup.3 represents hydrogen, a lower alkyl, a lower alkoxy, amino, a mono- or di-lower alkylamino, an amino-lower alkyl, a hydroxy-lower alkyl, a halo-lower alkyl, a lower alkoxy-lower alkyl, an acyloxy-lower alkyl, a lower alkoxycarbonyl-lower alkyl, an aryl or a heteroaryl, or R.sup.2 and R.sup.3 combinedly together form an alkylene having 1 to 2 carbon atoms; R.sup.4 and R.sup.5 are the same or different, and respectively represent hydrogen or a lower alkyl, or combinedly together form an alkylene having 2 to 5 carbon atoms; R.sup.6 represents hydroxyl group, formyloxy, an alkanoyloxy, a haloalkanoyloxy, a lower alkoxycarbonyloxy, an aroyloxy, a heteroaroyloxy, carbamoyloxy, a mono- or di-lower alkylcarbamoyloxy and R.sup.7 represents hydrogen, or R.sup.6 and R.sup.7 combinedly together form a bond and X and Y are the same or different, and respectively represent hydrogen, halogen, nitro, cyano, a lower alkyl, a lower alkoxy, a halo-lower alkyl, carboxyl, formyl, and alkanoyl, an aroyl, a halo-alkanoyl, carbamoyl, a lower alkylsulfinyl, an arylsulfinyl, a lower alkylsulfonyl, and arylsulfonyl, sulfonamido or a mono- or di-lower alkylsulfonamido, or their pharmaceutically acceptable salts and its pharmaceutical use.The compounds of the present invention exhibit remarkable and long lasting antihypertensive actions and peripheral vascular relaxant actions and therefore are useful as therapeutic medicines for hypertensive. Since they also display selective coronary vasodilating actions and the duration of actions are very long, they are of use as therapeutic medicines for cardiovascular disturbances such as angina pectoris and cardiac insufficiency.